SCHEMBL8834664

SCHEMBL8834664

c1coc(Cc2ccnnc2Cc2ccco2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CHRM2 P08172 1/20 0.32
PNP P00491 2/20 0.31
SMN1; SMN2 Q16637 3/20 0.31
KMT2A Q03164 2/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
MAPK1 P28482 3/20 0.31
KDM4E B2RXH2 2/20 0.31
MAPT P10636 2/20 0.31
MEN1 O00255 1/20 0.31
HTT P42858 1/20 0.31
BLM P54132 1/20 0.31
ALDH1A1 P00352 3/20 0.31
HPGD P15428 2/20 0.31
HSD17B10 Q99714 1/20 0.31
USP2 O75604 1/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8834668 0.74 ALDH1A1 (0.41) LMNACYP1A2CYP2D6CHRM2SMN1; SMN2
SCHEMBL1404275 0.70 CHRM2 (0.46) CHRM2KMT2AKDM4EMAPTMEN1
SCHEMBL9387184 0.69 GAA (0.40) CYP1A2CYP2D6PNPKMT2AKDM4E
SCHEMBL28895241 0.67 ALDH1A1 (0.36) LMNACYP1A2CYP2D6CHRM2SMN1; SMN2
SCHEMBL12069748 0.66 POLB (0.39) LMNACYP1A2PNPSMN1; SMN2KMT2A
SCHEMBL11004553 0.66 BACE1 (0.51) LMNACYP1A2CYP2D6PNPSMN1; SMN2
SCHEMBL7364036 0.64 MEN1 (0.38) CHRM2KMT2AKDM4EMAPTMEN1
SCHEMBL15366561 0.64 CHRM2 (0.36) CHRM2KMT2AKDM4EMAPTMEN1
SCHEMBL14713173 0.64 HSD17B10 (0.40) LMNACYP1A2CYP2D6PNPSMN1; SMN2
SCHEMBL11629972 0.63 HSPA5 (0.52) LMNACYP2D6SMN1; SMN2KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286964-A1 Liquid Bio-based Benzoxazine Resin Systems with Improved Processability and High Performance DREXEL UNIVERISTY (US) 2023-09-14 US claimed
WO-2022035579-A2 LIQUID BIO-BASED BENZOXAZINE RESIN SYSTEMS WITH IMPROVED PROCESSABILITY AND HIGH PERFORMANCE PALMESE GIUSEPPE RAFAELLO (US) 2022-02-17 WO claimed
US-20230286964-A1 Liquid Bio-based Benzoxazine Resin Systems with Improved Processability and High Performance DREXEL UNIVERISTY (US) 2023-09-14 US disclosed
WO-2022035579-A2 LIQUID BIO-BASED BENZOXAZINE RESIN SYSTEMS WITH IMPROVED PROCESSABILITY AND HIGH PERFORMANCE PALMESE GIUSEPPE RAFAELLO (US) 2022-02-17 WO disclosed
US-10221280-B2 Acrylated or methacrylated urethane oligomer without isocyanate ARKEMA FRANCE (FR) 2019-03-05 US disclosed
US-20160122473-A1 ACRYLATED OR METHACRYLATED URETHANE OLIGOMER WITHOUT ISOCYANATE ARKEMA FRANCE (FR) 2016-05-05 US disclosed
EP-0699712-B1 Vulcanized polyolefinic plastoelastomer composition and a process for its preparation ENICHEM SPA (IT) 1997-11-19 EP disclosed
US-5523356-A DYNAMICALLY VULCANIZED THERMOPLASTIC ELASTOMERS CONTAINING HOMO-OR COPOLYMERS OF PROPYLENE, ISOBUTYLENE, ETHYLENE, BUTADIENE, AND OTHER ALPHA-OLEFINS AND DIENES ENICHEM ELASTOMERI S.R.L. (IT) 1996-06-04 US disclosed
EP-0699712-A1 Vulcanized polyolefinic plastoelastomer composition and a process for its preparation ENICHEM ELASTOMERI S.r.l. (IT) 1996-03-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286964-A1 Liquid Bio-based Benzoxazine Resin Systems with Improved Processability and High Performance TBXAS1, BRIX1, BTD LMNA 814/4885CYP1A2 347/4885CYP2D6 1315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.